Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients

Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients...

Full description

Saved in:
Bibliographic Details
Published in:American journal of transplantation 2020-10, Vol.20 (10), p.2857-2866
Main Authors: Szczurek, Wioletta, Gąsior, Mariusz, Skrzypek, Michał, Szyguła‐Jurkiewicz, Bożena
Format: Article
Language:English
Subjects:
Allografts
basic (laboratory) research/science
complication
Female
heart (allograft) function/dysfunction
Heart Diseases
Heart transplantation
Heart Transplantation - adverse effects
heart transplantation/cardiology
Heart transplants
Humans
Inflammation
Limiting factors
Male
Middle Aged
Nicotinamide Phosphoribosyltransferase
Risk Factors
Vascular diseases
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3486-8399913cd529aa5b57d4e90ab9fe350e0e445c0fd835ae6e0d1776cd8ff21df3
container_end_page 2866
container_issue 10
container_start_page 2857
container_title American journal of transplantation
container_volume 20
creator Szczurek, Wioletta
Gąsior, Mariusz
Skrzypek, Michał
Szyguła‐Jurkiewicz, Bożena
description Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years, and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level (1.795 [1.539‐2.094]; P 
doi_str_mv 10.1111/ajt.15986
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2399838919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399838919</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3486-8399913cd529aa5b57d4e90ab9fe350e0e445c0fd835ae6e0d1776cd8ff21df3</originalsourceid><addsrcrecordid>eNp1kU1r3DAQhkVJadK0h_yBIMglPWwiWZYtHUNIvwj0svQqZqVRVottOZKcsP--ajfNodC5zDA8PAzzEnLG2RWvdQ27csWlVt0bcsI7xlYdb8XR6yzkMXmf844x3jeqeUeORSN61ff6hIw_Q_ZQwkQzpmWkNk4Wp5LqKk40ZAo5RxugoKPPoWypheQCWArDEB8S-EKfINtliDOU7Z5W0RYhFVoVU54HmApNaMMcqjV_IG89DBk_vvRTsv58t779urr_8eXb7c39yopWdSsltNZcWCcbDSA3snctagYb7VFIhgzbVlrmnRISsEPmeN931invG-68OCWXB-2c4uOCuZgxZItDvQbjkk1T_UoozXVFL_5Bd3FJUz3ONG3bcyU1l5X6dKBsijkn9GZOYYS0N5yZ3xGYGoH5E0Flz1-My2ZE90r-_XkFrg_Acxhw_3-Tufm-Pih_ATifkmM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447185915</pqid></control><display><type>article</type><title>Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients</title><source>Wiley</source><source>ScienceDirect Journals</source><creator>Szczurek, Wioletta ; Gąsior, Mariusz ; Skrzypek, Michał ; Szyguła‐Jurkiewicz, Bożena</creator><creatorcontrib>Szczurek, Wioletta ; Gąsior, Mariusz ; Skrzypek, Michał ; Szyguła‐Jurkiewicz, Bożena</creatorcontrib><description>Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years, and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level (1.795 [1.539‐2.094]; P &lt; .001) was significantly associated with CAV, and statin use was protective against CAV (0.504 [0.32‐0.793]; P = .003). The area under the receiver operating characteristic curve indicated an excellent discriminatory power of visfatin (0.9548 [0.9281‐0.9816]) for CAV detection. The cutoff value of 5.42 ng/mL for visfatin yielded a sensitivity of 89% and specificity of 91%. This is the first study to demonstrate that visfatin serum concentrations are independently associated with the incidence of CAV in HT recipients. Visfatin allows for simple and cheap detection of CAV given its excellent discriminatory ability and high sensitivity and specificity. In addition, we have found an independent association between the statin use and a lower risk of CAV. The serum concentration of visfatin may be a noninvasive and cost‐effective diagnostic for cardiac allograft vasculopathy with high discriminatory power, sensitivity, and specificity.</description><identifier>ISSN: 1600-6135</identifier><identifier>EISSN: 1600-6143</identifier><identifier>DOI: 10.1111/ajt.15986</identifier><identifier>PMID: 32378779</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Allografts ; basic (laboratory) research/science ; complication ; Female ; heart (allograft) function/dysfunction ; Heart Diseases ; Heart transplantation ; Heart Transplantation - adverse effects ; heart transplantation/cardiology ; Heart transplants ; Humans ; Inflammation ; Limiting factors ; Male ; Middle Aged ; Nicotinamide Phosphoribosyltransferase ; Risk Factors ; Vascular diseases</subject><ispartof>American journal of transplantation, 2020-10, Vol.20 (10), p.2857-2866</ispartof><rights>2020 The American Society of Transplantation and the American Society of Transplant Surgeons</rights><rights>2020 The American Society of Transplantation and the American Society of Transplant Surgeons.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3486-8399913cd529aa5b57d4e90ab9fe350e0e445c0fd835ae6e0d1776cd8ff21df3</cites><orcidid>0000-0001-9736-422X ; 0000-0003-3410-7407 ; 0000-0001-6775-1392 ; 0000-0001-7985-4612</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajt.15986$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajt.15986$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32378779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szczurek, Wioletta</creatorcontrib><creatorcontrib>Gąsior, Mariusz</creatorcontrib><creatorcontrib>Skrzypek, Michał</creatorcontrib><creatorcontrib>Szyguła‐Jurkiewicz, Bożena</creatorcontrib><title>Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients</title><title>American journal of transplantation</title><addtitle>Am J Transplant</addtitle><description>Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years, and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level (1.795 [1.539‐2.094]; P &lt; .001) was significantly associated with CAV, and statin use was protective against CAV (0.504 [0.32‐0.793]; P = .003). The area under the receiver operating characteristic curve indicated an excellent discriminatory power of visfatin (0.9548 [0.9281‐0.9816]) for CAV detection. The cutoff value of 5.42 ng/mL for visfatin yielded a sensitivity of 89% and specificity of 91%. This is the first study to demonstrate that visfatin serum concentrations are independently associated with the incidence of CAV in HT recipients. Visfatin allows for simple and cheap detection of CAV given its excellent discriminatory ability and high sensitivity and specificity. In addition, we have found an independent association between the statin use and a lower risk of CAV. The serum concentration of visfatin may be a noninvasive and cost‐effective diagnostic for cardiac allograft vasculopathy with high discriminatory power, sensitivity, and specificity.</description><subject>Allografts</subject><subject>basic (laboratory) research/science</subject><subject>complication</subject><subject>Female</subject><subject>heart (allograft) function/dysfunction</subject><subject>Heart Diseases</subject><subject>Heart transplantation</subject><subject>Heart Transplantation - adverse effects</subject><subject>heart transplantation/cardiology</subject><subject>Heart transplants</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Limiting factors</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nicotinamide Phosphoribosyltransferase</subject><subject>Risk Factors</subject><subject>Vascular diseases</subject><issn>1600-6135</issn><issn>1600-6143</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU1r3DAQhkVJadK0h_yBIMglPWwiWZYtHUNIvwj0svQqZqVRVottOZKcsP--ajfNodC5zDA8PAzzEnLG2RWvdQ27csWlVt0bcsI7xlYdb8XR6yzkMXmf844x3jeqeUeORSN61ff6hIw_Q_ZQwkQzpmWkNk4Wp5LqKk40ZAo5RxugoKPPoWypheQCWArDEB8S-EKfINtliDOU7Z5W0RYhFVoVU54HmApNaMMcqjV_IG89DBk_vvRTsv58t779urr_8eXb7c39yopWdSsltNZcWCcbDSA3snctagYb7VFIhgzbVlrmnRISsEPmeN931invG-68OCWXB-2c4uOCuZgxZItDvQbjkk1T_UoozXVFL_5Bd3FJUz3ONG3bcyU1l5X6dKBsijkn9GZOYYS0N5yZ3xGYGoH5E0Flz1-My2ZE90r-_XkFrg_Acxhw_3-Tufm-Pih_ATifkmM</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Szczurek, Wioletta</creator><creator>Gąsior, Mariusz</creator><creator>Skrzypek, Michał</creator><creator>Szyguła‐Jurkiewicz, Bożena</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9736-422X</orcidid><orcidid>https://orcid.org/0000-0003-3410-7407</orcidid><orcidid>https://orcid.org/0000-0001-6775-1392</orcidid><orcidid>https://orcid.org/0000-0001-7985-4612</orcidid></search><sort><creationdate>202010</creationdate><title>Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients</title><author>Szczurek, Wioletta ; Gąsior, Mariusz ; Skrzypek, Michał ; Szyguła‐Jurkiewicz, Bożena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3486-8399913cd529aa5b57d4e90ab9fe350e0e445c0fd835ae6e0d1776cd8ff21df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Allografts</topic><topic>basic (laboratory) research/science</topic><topic>complication</topic><topic>Female</topic><topic>heart (allograft) function/dysfunction</topic><topic>Heart Diseases</topic><topic>Heart transplantation</topic><topic>Heart Transplantation - adverse effects</topic><topic>heart transplantation/cardiology</topic><topic>Heart transplants</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Limiting factors</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nicotinamide Phosphoribosyltransferase</topic><topic>Risk Factors</topic><topic>Vascular diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szczurek, Wioletta</creatorcontrib><creatorcontrib>Gąsior, Mariusz</creatorcontrib><creatorcontrib>Skrzypek, Michał</creatorcontrib><creatorcontrib>Szyguła‐Jurkiewicz, Bożena</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szczurek, Wioletta</au><au>Gąsior, Mariusz</au><au>Skrzypek, Michał</au><au>Szyguła‐Jurkiewicz, Bożena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients</atitle><jtitle>American journal of transplantation</jtitle><addtitle>Am J Transplant</addtitle><date>2020-10</date><risdate>2020</risdate><volume>20</volume><issue>10</issue><spage>2857</spage><epage>2866</epage><pages>2857-2866</pages><issn>1600-6135</issn><eissn>1600-6143</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years, and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level (1.795 [1.539‐2.094]; P &lt; .001) was significantly associated with CAV, and statin use was protective against CAV (0.504 [0.32‐0.793]; P = .003). The area under the receiver operating characteristic curve indicated an excellent discriminatory power of visfatin (0.9548 [0.9281‐0.9816]) for CAV detection. The cutoff value of 5.42 ng/mL for visfatin yielded a sensitivity of 89% and specificity of 91%. This is the first study to demonstrate that visfatin serum concentrations are independently associated with the incidence of CAV in HT recipients. Visfatin allows for simple and cheap detection of CAV given its excellent discriminatory ability and high sensitivity and specificity. In addition, we have found an independent association between the statin use and a lower risk of CAV. The serum concentration of visfatin may be a noninvasive and cost‐effective diagnostic for cardiac allograft vasculopathy with high discriminatory power, sensitivity, and specificity.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32378779</pmid><doi>10.1111/ajt.15986</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9736-422X</orcidid><orcidid>https://orcid.org/0000-0003-3410-7407</orcidid><orcidid>https://orcid.org/0000-0001-6775-1392</orcidid><orcidid>https://orcid.org/0000-0001-7985-4612</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1600-6135
ispartof American journal of transplantation, 2020-10, Vol.20 (10), p.2857-2866
issn 1600-6135
1600-6143
language eng
recordid cdi_proquest_miscellaneous_2399838919
source Wiley; ScienceDirect Journals
subjects Allografts
basic (laboratory) research/science
complication
Female
heart (allograft) function/dysfunction
Heart Diseases
Heart transplantation
Heart Transplantation - adverse effects
heart transplantation/cardiology
Heart transplants
Humans
Inflammation
Limiting factors
Male
Middle Aged
Nicotinamide Phosphoribosyltransferase
Risk Factors
Vascular diseases
title Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Visfatin%20serum%20concentration%20is%20associated%20with%20cardiac%20allograft%20vasculopathy%20in%20heart%20transplant%20recipients&rft.jtitle=American%20journal%20of%20transplantation&rft.au=Szczurek,%20Wioletta&rft.date=2020-10&rft.volume=20&rft.issue=10&rft.spage=2857&rft.epage=2866&rft.pages=2857-2866&rft.issn=1600-6135&rft.eissn=1600-6143&rft_id=info:doi/10.1111/ajt.15986&rft_dat=%3Cproquest_cross%3E2399838919%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3486-8399913cd529aa5b57d4e90ab9fe350e0e445c0fd835ae6e0d1776cd8ff21df3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2447185915&rft_id=info:pmid/32378779&rfr_iscdi=true